What is the role of bortezomib-dexamethasone induction therapy in the treatment of multiple myeloma (MM)?

Updated: May 11, 2021
  • Author: Dhaval Shah, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

A study by Moreau et al determined that achievement of very good partial response (VGPR) after induction therapy is an important prognostic factor in patients undergoing autologous stem cell transplantation. [114] VGPR was significantly improved with bortezomib-dexamethasone induction therapy.

A study by Harousseau et al also concluded that this combination significantly improved postinduction and posttransplantation complete response/near response rate at at least VGPR rates compared with VAD. [115] Cavo et al also concluded that this combination represents a new standard of care for patients with multiple myeloma who are eligible for transplant. [116]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!